SEARCH:   Advanced

Blood, 1 November 2005, Vol. 106, No. 9, pp. 3223-3226. Prepublished online as a Blood First Edition Paper on July 12, 2005; DOI 10.1182/blood-2005-04-1742. This Article Full Text (PDF) All Versions of this Article: 2005-04-1742v1 106/9/3223    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mayr, C. Articles by Wendtner, C.-M. Search for Related Content PubMed PubMed Citation Articles by Mayr, C. Articles by Wendtner, C.-M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 28, 2005 Accepted June 29, 2005 Transduction of CLL cells by CD40 ligand (CD40L) enhances an antigen specific immune recognition by autologous T cells Christine Mayr, David M Kofler, Hildegard Buning, Dagmar Bund, Michael Hallek, and Clemens-Martin Wendtner* KKG Gene Therapy, GSF-National Research Center for Environment and Health, Munich, Germany; Medical Clinic III, Klinikum Grosshadern Medical Center(KGMC), Ludwig-Maximilians-University, Munich, Germany KKG Gene Therapy, GSF-National Research Center for Environment and Health, Munich, Germany; Medical Clinic III, Klinikum Grosshadern Medical Center(KGMC), Ludwig-Maximilians-University, Munich, Germany; Medical Clinic I, University of Cologne, Cologne, Germany Medical Clinic I, University of Cologne, Cologne, Germany; Gene Center, Ludwig-Maximilians-University, Munich, Germany KKG Gene Therapy, GSF-National Research Center for Environment and Health, Munich, Germany * Corresponding author; email: Clemens.Wendtner{at}uni-koeln.de. Several features of chronic lymphocytic leukemia (CLL) suggest that immune-based strategies may have therapeutic potential. A promising approach is provided by transduction of CLL cells with CD40L by viral vectors to enhance their immunogenicity. We compared the antigen presenting capacity of CD40L-transduced CLL cells with mock-transduced or CD40L-stimulated CLL cells (CD40-CLL). A significant higher number of T cells could be expanded using CD40L-transduced CLL cells as antigen presenting cells (APC) compared to the control group (p=0.008). Using five different CLL-associated tumor antigens including fibromodulin, MDM2, survivin, p53 and KW-13 we show in IFN- ELISPOT assays after 35 days of in vitro culture that also the number of antigen-specific autologous T cells was significantly higher when CD40L-transduced CLL cells were used as APC (p< 0.001). Thus, CD40L-transduced CLL cells are able to induce an antigen specific T cell response and might be superior to CD40-CLL cells for immune based therapeutic strategies in CLL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. P. Kater, M. H. J. van Oers, and T. J. Kipps Cellular immune therapy for chronic lymphocytic leukemia Blood, October 15, 2007; 110(8): 2811 - 2818. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020